TMCnet News
Myriad Genetics CEO Paul Diaz to Speak at 40th Annual J.P. Morgan Health Care ConferenceSALT LAKE CITY, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Paul J. Diaz, president and CEO of Myriad Genetics (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will provide an update on the execution of the company’s strategic transformation and growth plans at the 40th Annual J.P. Morgan Health Care Conference at 2:15 p.m. ET on Jan. 11, 2022. Diaz will discuss the growing role of genetic insights in context with industry trends, new commercial capabilities and products that advance health equity and enable healthcare providers to better detect, treat and prevent disease. He will share a progress report on the results of the company’s transformation and growth efforts as well as its strategic roadmap. The presentation will be available via a live audio webcast accessible at the following direct link or through the Myriad Genetics website in the investor information section. About Myriad Genetics Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, MyRisk, Myriad MyRisk, MyRisk Hereditary Cancer, MyChoice, MyPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice CDx, EndoPredict, Prequel, Foresight, GeneSight, RiskScore and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. Media Contact: Investor Contact: |